Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ALK status confers therapeutic sensitivity to Brigatinib in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved brigatinib for reimbursement as a monotherapy treatment option for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor, and whose ALK rearrangement has been demonstrated by an accurate and validated test method.
This statement is based on a regulatory approval from the Health Service Executive:
Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.